Breaking News Instant updates and real-time market news.

CNC

Centene

$61.02

1.29 (2.16%)

, WCG

WellCare

$115.96

1.75 (1.53%)

11:21
10/18/16
10/18
11:21
10/18/16
11:21

Evercore says UnitedHealth displaces Aetna for managed care deal in Missouri

Analysts at Evercore ISI noted that Centene (CNC) and Wellcare (WCG) announced managed care contract awards in Missouri, where they are incumbents. The firm also said that the state's contract database names UnitedHealth (UNH) as the third winner, replacing the third incumbent, Aetna (AET). The firm assumes that Centene and Wellcare will retain their existing lives and that Aetna's current lives and the expansion lives will be divided evenly among the three contract awardees. Evercore said it assumed a Missouri renewal for Centene and views the win as removing downside risk, adding that the loss is "manageable" for Aetna but could raise concerns about the Medicaid business in general.

CNC

Centene

$61.02

1.29 (2.16%)

WCG

WellCare

$115.96

1.75 (1.53%)

UNH

UnitedHealth

$142.88

8.75 (6.52%)

AET

Aetna

$111.09

2.6 (2.40%)

  • 18

    Oct

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 03

    Nov

  • 04

    Nov

  • 06

    Nov

  • 10

    Nov

  • 16

    Dec

CNC Centene
$61.02

1.29 (2.16%)

09/07/16
WEDB
09/07/16
NO CHANGE
WEDB
Centene weakness overdone, says Wedbush
After Leerink downgraded Centene and the stock fell 5%, Wedbush analyst Sarah James says that the decline in the stock is overdone. James thinks that the company could benefit in the near-term from the resolution of California PPO price increases and benefit design changes. The analyst thinks that the company should continue to benefit from Medicaid growth, and she expects the stock to rebound in the wake of appearances by Centene's management at conferences this week. James keeps an $85 price target and Outperform rating on the shares.
09/06/16
UBSW
09/06/16
NO CHANGE
Target $80
UBSW
Buy
UBS sees Centene weakness as a buying opportunity
UBS analyst A.J. Rice believes Centene is approaching the end of its discussions with California regulators regarding potential changes in its off-exchange PPO plan. The analyst talked with the company's management that said the state is "comfortable" approving certain of its requested benefit design changes, which along with the 23% price increase the company also requested would get Centene to earnings breakeven on the PPO plan in 2017. Regulators are expected to announce their final position by the end of the month, he notes. The analyst sees the weakness in the stock as a buying opportunity, and reiterates a Buy rating and $80 price target on the shares.
09/06/16
09/06/16
DOWNGRADE
Target $80

Market Perform
Centene downgraded to Market Perform at Leerink
As previously reported, Leerink analyst Ana Gupte downgraded Centene to Market Perform from Outperform, with $80 price target, as she expects below consensus EPS achievability in 2017. The analyst believes the absence of integration of long-term care contracts, combined with the ability to lower Acute Care spend, is likely to remain an earnings headwind. Further, Gupte thinks margins in the core Medicaid business look to have peaked.
09/22/16
EVER
09/22/16
INITIATION
Target $79
EVER
Buy
Centene initiated with a Buy at Evercore ISI
Evercore ISI initiated Centene with a Buy and a $79 price target.
WCG WellCare
$115.96

1.75 (1.53%)

05/13/16
RBCM
05/13/16
NO CHANGE
RBCM
Health insurance weakness on court decision overdone, says RBC Capital
RBC Capital believes that the weakness in health insurer stocks in response to a federal judge's decision in the House versus Burwell case is overdone. The firm predicts that the decision will be overturned on appeal. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
06/13/16
SUSQ
06/13/16
NO CHANGE
Target $136
SUSQ
Positive
WellCare price target raised to $136 from $107 at Susquehanna
Susquehanna raised its price target on WellCare to $136 from $107 based on the view that it remains the divestee of choice for the Aetna (AET) and Humana (HUM) transaction. Susquehanna reiterated its Positive rating on WellCare shares.
06/15/16
LEER
06/15/16
NO CHANGE
Target $155
LEER
Outperform
Cigna could pursue other options if Anthem deal breaks, says Leerink
Leerink analyst Ana Gupte sees an acquisition of WellCare (WCG) or Molina Healthcare (MOH) by Cigna (CI) as potentially likely if the Anthem (ANTM) deal breaks. A Cigna combination with WellCare or Molina can be "strategically attractive" given the entry for Cigna into Medicaid and particularly Dual Eligibles markets, the analyst tells investors in a research note. While Gupte does not expect either company to entertain a transaction in the near-term, she believes a deal could be possible at the right price. The analyst recently lowered her Anthem-Cigna deal probability from 70% to under 50% on antitrust challenges exacerbated by management conflicts. She has an Outperform rating and $155 price target on Cigna's shares.
07/11/16
LEER
07/11/16
NO CHANGE
LEER
Outperform
WellCare more likely to win bid for Aetna Medical Advantage assets, says Leerink
Leerink analyst Ana Gupte views the reports that WellCare (WCG) and Centene (CNC) have bid for the package of Medical Advantage assets that are being auctioned off by Aetna (AET) to help close its transaction with Humana (HUM) as credible. The analyst sees WellCare as more likely to win the assets in this auction given their existing Medical Advantage presence. Leerink has an Outperform rating on both WellCare and Centene shares.
UNH UnitedHealth
$142.88

8.75 (6.52%)

09/22/16
EVER
09/22/16
INITIATION
Target $155
EVER
Buy
UnitedHealth initiated with a Buy at Evercore ISI
Evercore ISI initiated UnitedHealth with a Buy and a $155 price target.
09/22/16
PIPR
09/22/16
NO CHANGE
Target $155
PIPR
Overweight
UnitedHealth won VA contract worth $1B per year, says Piper Jaffray
Piper Jaffray analyst Sean Wieland says UnitedHealth unit Optum has won a contract with the U.S. Department of Veterans Affairs to provide medical disability examinations. The analyst estimates the contract, awarded to Optum wholly owned subsidiaries Logistics Health and Medical Support Los Angeles, represents $1B per year. Wieland estimates the award will be neutral to earnings in year one and become accretive in 2018. He reiterates an Overweight rating on UnitedHealth shares with a $155 price target.
09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
AET Aetna
$111.09

2.6 (2.40%)

08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.
09/22/16
EVER
09/22/16
INITIATION
Target $128
EVER
Buy
Aetna initiated with a Buy at Evercore ISI
Evercore ISI analyst Michael Newshel initiated Aetna with a Buy and a $128 price target.
09/29/16
09/29/16
DOWNGRADE

Underweight
Pacific Crest cuts Fitbit to sell, sees share downside to $11
Pacific Crest analyst Brad Erickson downgraded Fitbit (FIT) to Underweight from Sector Weight after his channel checks indicated that Charge 2, the company's flagship holiday product, is off to a slow start. Underweight is Pacific Crest's equivalent of a sell rating. Charge 2 inventory is accumulating in the channel and sell-through is below initial Blaze/Alta levels, Erickson tells investors in a research note. The analyst continues to believe that a large portion of Fitbit owners stop using the device within months. Further, he views the corporate wellness deal between Aetna (AET) and Apple (AAPL) as a "substantial negative" for Fitbit. Erickson sees downside to $11 for shares of Fitbit. The stock closed yesterday up 17c to $16.70.
10/12/16
CANT
10/12/16
NO CHANGE
Target $225
CANT
Buy
Humana CMS star rating news shouldn't impact Aetna deal, says Cantor
After Humana (HUM) reported that the Centers for Medicare and Medicaid Services reported that the percentage of the company's membership in 4-Star plans or higher declined to approximately 37% from approximately 78% in the prior year, Cantor analysts said they do not expect the news to impact 2017 enrollment or the pending Aetna (AET) deal. The firm reiterates its Buy rating and $225 price target on Humana shares.

TODAY'S FREE FLY STORIES

PVG

Pretium Resources

$11.61

-0.04 (-0.34%)

14:45
01/17/18
01/17
14:45
01/17/18
14:45
Options
Pretium Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
01/17/18
01/17
14:45
01/17/18
14:45
General news
Breaking General news story  »

Chicago Federal Reserve…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

, GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

14:39
01/17/18
01/17
14:39
01/17/18
14:39
Hot Stocks
Google introduces Cloud AutoML to help businesses use machine learning »

In a blog post, Google…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

CBS

CBS

$59.44

0.01 (0.02%)

, VIAB

Viacom

$31.38

-2.38 (-7.05%)

14:37
01/17/18
01/17
14:37
01/17/18
14:37
Periodicals
Shari Redstone renews push to merge CBS, Viacom, WSJ reports »

Shari Redstone is…

CBS

CBS

$59.44

0.01 (0.02%)

VIAB

Viacom

$31.38

-2.38 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 15

    Feb

JBHT

J.B. Hunt

$120.64

-0.42 (-0.35%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Technical Analysis
Technical Earnings Preview: J.B. Hunt near life highs before earnings »

At time of writing and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$31.91

-0.44 (-1.36%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Hot Stocks
Deason reports 6% stake in Xerox, demands disclosure of JV pact with Fujifilm »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
01/17/18
01/17
14:35
01/17/18
14:35
General news
Treasury Action: yields held near highs »

Treasury Action: yields…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

, VNRX

VolitionRx

$2.95

0.0441 (1.52%)

14:31
01/17/18
01/17
14:31
01/17/18
14:31
Hot Stocks
Analysts stay bullish on Exact Sciences after ASCO abstract prompts pullback »

Shares of Exact Sciences…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

VNRX

VolitionRx

$2.95

0.0441 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

  • 29

    Mar

AG

First Majestic

$7.36

0.0106 (0.14%)

14:30
01/17/18
01/17
14:30
01/17/18
14:30
Options
Far upside call buyers in First Magestic as shares trade flat »

Far upside call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$71.16

-0.05 (-0.07%)

14:26
01/17/18
01/17
14:26
01/17/18
14:26
Hot Stocks
Vornado raises dividend to 63c per share »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALX

Alexander's

$379.05

-3.045 (-0.80%)

14:24
01/17/18
01/17
14:24
01/17/18
14:24
Hot Stocks
Alexander's boosts quarterly dividend to $4.50 per share »

Alexander's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$147.07

0.21 (0.14%)

14:22
01/17/18
01/17
14:22
01/17/18
14:22
Hot Stocks
USPTO board says Janssen Oncology patent claims unpatentable »

In a final written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

LOCO

El Pollo Loco

$10.10

-0.2 (-1.94%)

14:20
01/17/18
01/17
14:20
01/17/18
14:20
Options
Bullish option flow in El Pollo Loco »

Bullish option flow in El…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
01/17/18
01/17
14:20
01/17/18
14:20
General news
Fed's Beige Book said the economy continued to expand »

Fed's Beige Book…

$NSD

NASDAQ Market Internals

14:17
01/17/18
01/17
14:17
01/17/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/17/18
01/17
14:16
01/17/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRSP

Crispr Therapeutics

$27.18

-1.34 (-4.70%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Recommendations
Crispr Therapeutics analyst commentary  »

Piper says European…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$54.72

0.12 (0.22%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Technical Analysis
Technical Earnings Preview: Morgan Stanley near 52-week high before news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

INTC

Intel

$43.14

-0.1 (-0.23%)

14:10
01/17/18
01/17
14:10
01/17/18
14:10
Options
Large block of puts in Intel as shares advance »

Large block of puts in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

WRB

W. R. Berkley

$70.12

0.7 (1.01%)

14:09
01/17/18
01/17
14:09
01/17/18
14:09
Hot Stocks
W. R. Berkley combines professional liability units »

W. R. Berkley announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ONTX

Onconova

$1.74

-0.0901 (-4.92%)

14:05
01/17/18
01/17
14:05
01/17/18
14:05
Downgrade
Onconova rating change  »

Onconova downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CY

Cypress Semiconductor

$16.90

-0.17 (-1.00%)

14:05
01/17/18
01/17
14:05
01/17/18
14:05
Options
Cypress Semiconductor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
01/17/18
01/17
14:05
01/17/18
14:05
General news
Apple tax repatriation windfall may total $38 B »

Apple tax repatriation…

14:04
01/17/18
01/17
14:04
01/17/18
14:04
General news
Beige Book says employment, wages grew at modest pace »

The latest Beige Book…

14:03
01/17/18
01/17
14:03
01/17/18
14:03
General news
Fed's Beige Book shows 11 Districts reporting modest to moderate gains »

The Federal Reserve Beige…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.